Literature DB >> 9012483

Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma.

C A Bandera1, H Takahashi, K Behbakht, P C Liu, V A LiVolsi, I Benjamin, M A Morgan, S A King, S C Rubin, J Boyd.   

Abstract

Previous allelotyping studies of epithelial ovarian carcinoma suggest that loss of heterozygosity on chromosome 14q may be a common genetic alteration in this tumor type. The purpose of this study was to determine a precise frequency of chromosome 14q allelic loss in ovarian carcinomas and to define a minimal region(s) of deletion. Seventy-six ovarian carcinomas representative of the complete spectrum of grade, stage, and histological subtype were selected for PCR-based deletion mapping analysis using 15 highly polymorphic microsatellite markers spanning the length of this chromosome arm. Loss of heterozygosity was observed in 49% of the tumors studied, placing 14q among the most frequently affected chromosomal regions in ovarian cancer. Deletions were observed in all tumor grades and stages and in all histological subtypes except tumors of low malignant potential. Deletion of the entire chromosome arm was rare; the majority of tumors displayed partial losses, providing an informative basis for detailed deletion mapping. Two distinct minimal regions of deletion were delineated. One region was defined by markers D14S80 and D14S75 at 14q12-13, and the other region was defined by markers D14S65 and D14S267 at 14q32. These data implicate the involvement of two tumor suppressor genes on chromosome 14q in a substantial fraction of ovarian carcinomas.

Entities:  

Mesh:

Year:  1997        PMID: 9012483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  The role of HSAL (SALL) genes in proliferation and differentiation in normal hematopoiesis and leukemogenesis.

Authors:  Li Chai
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

3.  Zinc finger protein sall2 is not essential for embryonic and kidney development.

Authors:  Akira Sato; Yuko Matsumoto; Urara Koide; Yuki Kataoka; Nobuaki Yoshida; Takashi Yokota; Makoto Asashima; Ryuichi Nishinakamura
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 4.  Estrogen, male dominance and esophageal adenocarcinoma: is there a link?

Authors:  Huiqi Yang; Olga A Sukocheva; Damian J Hussey; David I Watson
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

5.  A tumor host range selection procedure identifies p150(sal2) as a target of polyoma virus large T antigen.

Authors:  D Li; K Dower; Y Ma; Y Tian; T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

6.  Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.

Authors:  Chang K Sung; Dawei Li; Erik Andrews; Ronny Drapkin; Thomas Benjamin
Journal:  Mol Oncol       Date:  2012-12-12       Impact factor: 6.603

7.  Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma.

Authors:  Arthur Kwok Leung Cheung; Hong Lok Lung; Josephine Mun Yee Ko; Yue Cheng; Eric J Stanbridge; Eugene R Zabarovsky; John M Nicholls; Daniel Chua; Sai Wah Tsao; Xin-Yuan Guan; Maria Li Lung
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

8.  p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP).

Authors:  Dawei Li; Yu Tian; Yupo Ma; Thomas Benjamin
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Cloning, chromosomal localization and promoter analysis of the human transcription factor YY1.

Authors:  Y L Yao; B R Dupont; S Ghosh; Y Fang; R J Leach; E Seto
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

10.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Authors:  Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin
Journal:  Breast Cancer Res       Date:  2009-05-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.